Clinical trial readout dates for Disc Medicine Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is May 2027.
The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.
| Phase 3 DISC-1459 Erythropoietic Protoporphyria (EPP); X-Linked Protoporphyria (XLP) · NCT06910358 | September 2026 Primary data collected |
| Phase 1/2 DISC-0974 Myelofibrosis; Anemia; Anemia · NCT05320198 | May 2027 Recruiting |
| Phase 2 DISC-3405 Polycythemia Vera (PV) · NCT06985147 | July 2027 Ongoing |
| Phase 2/3 DISC-1459 Erythropoietic Protoporphyria · NCT05883748 | June 2028 Enrolling |
Disc Medicine Inc. reported $683M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-05). Its net loss for that quarter was $60M; at that rate the cash would last about 11 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-05 |
| 8-K Other Events — often topline trial data | 2026-10-22 |